Deals Of The Week: Sanofi/Micromet, Cephalon/BioAssets, GSK/SuperGen...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
This is Sanofi-Aventis' third oncology partnership this year, as it continues to seek new cancer drugs to replace Taxotere and Eloxatin.
The CRO looks to remake itself and invest $100 million in Celtic Pharmaceutical Holdings, which wants mid-stage development projects.
GlaxoSmithKline will pay $5 million upfront for an option to develop cancer drugs based on epigenetic targets; deal is GSK's sixth option-alliance this year.